| OR | 95% CI | P value | |
|---|---|---|---|
| (Intercept) | 0.01 | (0.01‐0.02) | .0000 |
| Baseline age category | |||
| 18 to <40 | ref | … | … |
| 40 to <65 | 0.89 | (0.68‐1.19) | .4289 |
| 65 to <75 | 1.91 | (1.41‐2.62) | .0000 |
| 75+ | 1.47 | (1.09‐2.02) | .0125 |
| Sex | |||
| Male | ref | … | … |
| Female | 1.40 | (1.17‐1.69) | .0003 |
| Region | |||
| Northeast | ref | … | … |
| North Central | 0.89 | (0.72‐1.10) | .2634 |
| South | 0.80 | (0.66‐0.98) | .0326 |
| West | 0.91 | (0.70‐1.19) | .5029 |
| Unknowna | … | … | … |
Abbreviations: CI, confidence interval; OR, odds ratio.
a
Not estimable as there was only 66 patients in this group and none had gone on to use target therapies during their 24‐month follow‐up.